Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level

Acta Medica Okayama

Volumn 60, Issue 2, 2006, Pages 77-84

  Ohta, Takeyuki ^a   Sakaguchi, Kohsaku ^a   Fujiwara, Akiko ^a   Fujioka, Shin Ichi ^a   Iwasaki, Yoshiaki ^a   Makino, Yasuhiro ^b   Araki, Yasuyuki ^c   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b IWAKUNI NATIONAL HOSPITAL   (Japan)

^c HIROSHIMA CITY HOSPITAL   (Japan)

Author keywords

Albumin level; Chronic hepatitis C; Fibrosis index; Fibrosis stage; Platelet count

Indexed keywords

SERUM ALBUMIN;

ADULT; ARTICLE; BLOOD; COHORT ANALYSIS; FEMALE; HEPATITIS C; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; MALE; METABOLISM; MIDDLE AGED; THROMBOCYTE COUNT; VALIDATION STUDY;

ADULT; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX;

HEPATITIS C VIRUS;

EID: 33646777824     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kieman TW and Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology (1981) 1: 431-435.
2. Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol (1991) 13: 372-374.
3. Desmet VJ, Gerber M, Hoofnagle JH, Manns M and Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology (1994) 19: 1513-1520.
4. The French METAVIR Cooperative Study Group: Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology (1994) 24: 15-20.
5. Bedossa P, Poynard T, for the METVIR Cooperative Study Group: An algorithm for grading of activity in chronic hepatitis C. Hepatology (1996) 24: 289-293.
6. Williams AL and Hoofnagle JH: Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology (1988) 95: 734-739.
7. Bonacini M, Hadi G, Govindarajan S and Lindsay KL: Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gstroenterol (1997) 92: 1302-1304.
8. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Tsubota A, Suzuki F, Arase Y, Murashima N, Chayama K and Kumada H: Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatology Res (2000) 18: 252-266.
9. Pohl A, Behling C, Oliver D, Kilani M, Monson P and Hassanein T: Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol (2001) 96: 3142-3146.
10. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, for the MULTIVIC Group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 357: 1069-1075.
11. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D and Easley K: The role of liver biopsy in chronic hepatitis C. Hepatology (2001) 33: 196-200.
12. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM and Rodes J: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 36: 986-992.
13. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS and Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 38: 518-526.
14. Poynard T and Bedossa P: Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Group. J Viral Hepatitis (1997) 4: 199-208.
15. Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, Kato N, Yoshida H, Shiina S and Omata M: Platelet count reflects stage of chronic hepatitis C. Hepatology Res (1999) 15: 192-200.
16. Coverdale SA, Samarasinghe DA, Lin R, Kench J, Byth K, Khan MH, Crewe E, Liddle C, George J and Farrell GC: Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. Am J Gastroenterol (2003) 98: 1384-1390.
17. Child CG III and Turcotte JG: Surgery and portal hypertension. in The liver and portal hypertension, Child CG III ed, WB Saunders, Philadelphia (1964) pp 1-85.
18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 60: 646-649.
19. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T, for the MULTIVIRC Group: Biochemical markers of liver fibrosis: a comparison with histological features in patients with chronic hepatitis C. Am J Gastroenterol (2002) 97: 2419-2425.
20. Afdhal NH and Nunes D: Evaluation of liver fibrosis: A concise review. Am J Gastroenterol (2004) 99: 1160-1174.
21. Yoshioka K, higashi Y, Yamada M, Aiyama T, Takayanagi M, Tanaka K, Okumura A, Iwata K and Kakumu S: Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver (1995) 15: 57-62.
22. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C and Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (1998) 352: 1426-1432.
23. Takano S, Yokosuka O, Imazeki F, Tagawa M and Omata M: Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology (1995) 21: 650-655.
24. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G and Omata M, for the IHIT Study Group: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med (1999) 131: 174-181.
25. Bedossa P, Dargere D and Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 38: 1449-1457.